Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease

  • US 9,187,559 B2
  • Filed: 02/20/2015
  • Issued: 11/17/2015
  • Est. Priority Date: 04/09/2004
  • Status: Active Grant
First Claim
Patent Images

1. A multiple-variable dose method for treating idiopathic inflammatory bowel disease in a human subject in need thereof, comprising subcutaneously administering to the human subject:

  • a first dose of 160 mg of adalimumab administered to the human subject within a day; and

    a second dose of 80 mg of adalimumab administered to the human subject within a day, wherein the second dose is administered two weeks following administration of the first dose.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×